Target Market Segments
Point of Care Testing
The point of care testing market was
valued at $11.3 billion in 2007. It is the fastest-growing segment of
the $33.6 billion diagnostics market, and is projected to reach $18.7
billion by 2011.
LeukoDx management is experienced in
tackling the challenges that most influence success in this market -
regulatory guidelines, reimbursement issues, protecting intellectual
property and technology infrastructure needs. Preparation has been made
to address these factors and LeukoDx is confident that we will be
competitive in the market.
Flow Cytometry
flow cytometry has a market value
around $1.5 billion, and by 2015 will have an estimated value of $3.6
billion. The technology is widely applicable in such fields as
molecular, marine and plant biology, protein engineering, pathology and
immunology.
In today's flow cytometer market,
short-term growth will be driven by smaller, more robust devices with
multiple applications to meet research and clinical sector needs. In
the long term, next-generation integrated point of care miniature
systems will drive growth. These machines do not exist today: LeukoDx's
platform technology addresses both of these growth targets and can be
brought to market within three years.
Currently, flow cytometers are large,
expensive, complicated, require a highly trained lab technician to
operate and can take over a week to present test resuts. This prevents
rapid response in patient care and severely limits access to the
technology. The LeukoDx technology will revolutionize the market by
offering a device that has all the technology in a smaller, less
expensive and easier to use device that will give results in 20 minutes.
